381 related articles for article (PubMed ID: 32375689)
1. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
2. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
[TBL] [Abstract][Full Text] [Related]
3. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
[TBL] [Abstract][Full Text] [Related]
4. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
[TBL] [Abstract][Full Text] [Related]
6. Does full HPV genotyping perform similarly well in clinician-collected cervical samples and self-collected vaginal samples when using the CLART HPV4S assay?
Solnæs JV; Njor SH; Tranberg M
BMC Womens Health; 2023 Feb; 23(1):78. PubMed ID: 36823528
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
8. Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.
Ejegod DM; Rebolj M; Bonde J
BMC Cancer; 2015 Apr; 15():216. PubMed ID: 25886410
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
[TBL] [Abstract][Full Text] [Related]
10. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
11. VALGENT: A protocol for clinical validation of human papillomavirus assays.
Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
[TBL] [Abstract][Full Text] [Related]
12. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
[TBL] [Abstract][Full Text] [Related]
13. The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.
Ejegod D; Bottari F; Pedersen H; Sandri MT; Bonde J
J Clin Microbiol; 2016 Sep; 54(9):2267-72. PubMed ID: 27307461
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples.
Avian A; Clemente N; Mauro E; Isidoro E; Di Napoli M; Dudine S; Del Fabro A; Morini S; Perin T; Giudici F; Cammisuli T; Foschi N; Mocenigo M; Montrone M; Modena C; Polenghi M; Puzzi L; Tomaic V; Valenti G; Sola R; Zanolla S; Vogrig E; Riva E; Angeletti S; Ciccozzi M; Castriciano S; Pachetti M; Petti M; Centonze S; Gerin D; Banks L; Marini B; Canzonieri V; Sopracordevole F; Zanconati F; Ippodrino R
J Transl Med; 2022 May; 20(1):231. PubMed ID: 35581584
[TBL] [Abstract][Full Text] [Related]
16. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
17. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.
Sun P; Song Y; Ruan G; Mao X; Kang Y; Dong B; Lin F
J Gynecol Oncol; 2017 Sep; 28(5):e50. PubMed ID: 28657218
[TBL] [Abstract][Full Text] [Related]
19. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
